[ad_1]
On Saturday, Norwegian health officials reported that three health workers were hospitalized for blood clots, bleeding and abnormally low platelet counts in the blood. All these people are under 50 years old and have been vaccinated with the first dose of the vaccine from the English and Swedish company.
One of the three people, a woman in good health, died of a brain hemorrhage on Sunday, authorities said. The woman was hospitalized on Thursday, about a week after the vaccination.
“We cannot confirm or deny that this is in any way related to the vaccine,” Steinar Madsen, an official at the Norwegian Medicines Agency, told reporters.
The other two people’s condition is reportedly stable.
Another health worker, under the age of 40, died in Norway on Friday, 10 days after being vaccinated with the same vaccine. There were other similar deaths in Europe, such as Austria and Denmark.
The European Medicines Agency (EMA) is investigating the circumstances of these cases to determine if there is a link to the vaccine.
The World Health Organization (WHO) said Friday that “no one is proving” that the AstraZeneca vaccine should not be used. The manufacturer itself claims that the vaccine is safe.
Norwegian officials say AstraZeneca has vaccinated about 130,000 people in the country before stopping it. people.
Other countries that have suspended vaccination against AstraZeneca for similar reasons include Denmark, Iceland, Bulgaria, Ireland, the Netherlands, France, Italy, and Germany. Denmark was the first to do so on Thursday, after one death.
The Danish Medicines Agency announced on Monday that the victim was a 60-year-old woman diagnosed with blood clots, low platelet counts and bleeding after vaccination.
The agency said that people who had been vaccinated with AstraZeneca in the past two weeks were aware of possible symptoms such as unusual bruising, bleeding, severe headache or abdominal pain.
One dose of the AstraZeneca vaccine has been administered in Denmark to about 150,000 people. people and two 583 people.
[ad_2]
